Overdose deaths in United States fell last year in largest one-year decline on record
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors.
Pharmaceutical
-
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More -
IBJ Podcast: The risks tariffs pose to Indiana’s manufacturing-heavy economy
President Trump wasted little time turning to economic policy once his second term began, imposing or threatening to impose a barrage of tariffs on many of Indiana’s trading partners.
Read More -
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Read More -
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Read More
Articles
Trump signs order setting 30-day deadline for drugmakers to lower prescription drug costs
The sweeping executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the United States or face new limits over what the government will pay.
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
Trump promises to order that United States pay same price other nations do for some drugs
The proposal, expected to be announced by President Trump on Monday, will face fierce opposition from the pharmaceutical industry.
Trump drug price idea could cost industry $1 trillion, lobbying group says
The idea, floated by the White House as a way to help pay for the president’s tax cut plan, blindsided the pharmaceutical industry and has prompted a furious lobbying campaign.
Lilly shares plunge after CVS Health drops Zepbound from preferred coverage
CVS Health’s pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.
Walgreens to pay up to $350M in opioid settlement
The U.S. Department of Justice accused the pharmacy of illegally filling millions of prescriptions in the last decade for opioids and other controlled substances.
Roche picks Indiana for new plant, expanded operations as part of $50B investment in United States
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
Lilly promises to make weight-loss pill in United States in reshoring push
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump orders new efforts to lower drug prices
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
Irish pharma exports to United States surge amid tariff threat
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer ends development of potential pill obesity treatment
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
FDA reverses course on telework after layoffs, resignations threaten basic operations
Weeks after ordering all Food and Drug Administration employees back into the office, the agency is allowing some of its most prized staffers to work remotely.
Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
Trump administration nixes plan to cover anti-obesity drugs through Medicare
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Johnson & Johnson plans $55B in United States investments
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
Purdue Pharma submits opioid lawsuit settlement plan, including up to $7B from Sacklers
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company in the latest plan to settle thousands of lawsuits.
Zepbound raises profile of Lilly’s direct-to-consumer sales initiative
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk cuts Wegovy prices, following similar move for Zepbound by Eli Lilly
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.